• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Assessment of renal response in Tunisian patients with proliferative lupus nephritis under three different induction immunosuppressive agents: A prognostic retrospective study.

作者信息

Somai Mehdi, Daoud Fatma, Arbaoui Ibrahim, Boukhzar Rihem, Ben Dhaou Besma, Bellali Hedia, Boussema Fatma, Rachdi Imene, Aydi Zohra

机构信息

Internal Medicine Department, Habib Thameur Hospital, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Preventive and Community Medicine Department, Habib Thameur Hospital, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

出版信息

Lupus. 2024 Dec;33(14):1615-1625. doi: 10.1177/09612033241289479. Epub 2024 Oct 3.

DOI:10.1177/09612033241289479
PMID:39360731
Abstract

OBJECTIVE

The aim of our study was to evaluate the renal response (RR) of three immunosuppressive protocols in the induction treatment of proliferative lupus nephritis (PLN) in a Tunisian population.

METHODS

We performed a retrospective prognostic cohort study in the Internal Medicine Department of the Habib Thameur University Hospital in Tunis from January 2000 to December 2023, and included kidney biopsy proven proliferative lupus nephritis patients. Three induction treatments were compared: High CYP regimen: glucocorticoids (GC) + IV cyclophosphamide (CYP) in monthly pulses of 0.7 g/m2 for 6 months; Low CYP regimen: GC + IV CYP in biweekly pulses of 500 mg for 3 months; and MMF regimen: GC + oral MMF 1.5 g twice daily for 6 months. The primary endpoint was the incidence of RR (complete and partial remission) at one year post-diagnosis. The additional outcomes were end-stage kidney disease (ESKD), severe adverse events (AEs) and death.

RESULTS

Our study included 78 PLN patients (High CYP: 17, Low CYP: 40, MMF: 21). The study found that 94.1% of patients receiving High CYP achieved the primary endpoint, RR, compared to 67.5% of those receiving Low CYP and 61.9% in the MMF group. For the additional outcomes, there were 3 cases of ESKD, all in the Low CYP group, 5 cases of death (4 in the Low CYP group and 1 in the MMF group), and 20 cases of severe AEs, all of which were severe infections (5 in the High CYP group, 12 in the Low CYP group, and 3 in the MMF group). Multivariate analysis showed that the High CYP regimen was more associated with RR than the MMF regimen, with an adjusted OR of 9.846 (95% CI: 1.087-98.210); = 0.042. Multivariate analysis did not show statistically significant differences between the High CYP regimen and the Low CYP regimen in terms of RR.

CONCLUSION

As an induction treatment for PLN, the High CYP regimen was strongly associated with a higher rate of RR than the MMF regimen. There were no statistically significant differences between the High CYP regimen and the Low CYP regimen in terms of RR.

摘要

相似文献

1
Assessment of renal response in Tunisian patients with proliferative lupus nephritis under three different induction immunosuppressive agents: A prognostic retrospective study.
Lupus. 2024 Dec;33(14):1615-1625. doi: 10.1177/09612033241289479. Epub 2024 Oct 3.
2
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
3
Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.基于环磷酰胺和霉酚酸酯的方案治疗狼疮肾炎的长期结局。
Lupus. 2020 Jul;29(8):845-853. doi: 10.1177/0961203320926256. Epub 2020 May 21.
4
Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.霉酚酸酯与环磷酰胺治疗印度狼疮性肾炎患者:哪种效果更佳?单中心经验
Saudi J Kidney Dis Transpl. 2017 Sep-Oct;28(5):1069-1077. doi: 10.4103/1319-2442.215147.
5
Treatment for lupus nephritis.狼疮性肾炎的治疗。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3.
6
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.比较儿童关节炎和风湿病研究联盟针对青少年增殖性狼疮性肾炎诱导治疗的共识治疗方案的初步研究。
Pediatr Rheumatol Online J. 2018 Oct 22;16(1):65. doi: 10.1186/s12969-018-0279-0.
7
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.增殖性狼疮性肾炎的维持治疗:霉酚酸酯、硫唑嘌呤和静脉注射环磷酰胺。
Lupus. 2005;14 Suppl 1:s33-8. doi: 10.1191/0961203305lu2115oa.
8
Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.在增殖性狼疮性肾炎中,采用短期大剂量静脉注射环磷酰胺随后使用霉酚酸酯进行诱导治疗。
Neth J Med. 2014 Nov;72(9):481-90.
9
Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis.霉酚酸酯与静脉注射脉冲环磷酰胺作为增殖性狼疮性肾炎诱导治疗的疗效及安全性比较
Iran J Kidney Dis. 2018 Oct;12(5):288-292.
10
Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.霉酚酸酯与环孢素A联合多靶点治疗诱导难治性狼疮性肾炎
Lupus. 2018 Jul;27(8):1358-1362. doi: 10.1177/0961203318758508. Epub 2018 Feb 15.